Negócios · 09/01/19951 min de leitura
Review of Regulations for General Biologics and Licensing and for Blood Establishments and Blood Products; Public Meeting
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA) is announcing a public meeting for interested persons to express their comments regarding the biologics regulations that the agency intends to review (21 CFR parts 600, 601, 606, 607, 610, 640, and 660). In the Federal Register of June 3, 1994 (59 FR 28821 and 28822, respectively), FDA issued two documents, ``Review of General Biologics and Licensing Regulations'' (Docket No. 94N-0066) and ``Review of Regulations for Blood Establishments and Blood Products'' (Docket No. 94N-0080), that announced that FDA was intending to review certain biologics regulations and requested public comments regarding those regulations. The comment periods have been extended twice and will close on February 13, 1995. The purpose of the public meeting is to allow additional opportunity for public comment concerning the biologics regulations that the agency is reviewing.